NextCure Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
NXTC
- Investments
-
1
- Share Price
-
$6.89
- (As of Thursday Closing)
NextCure General Information
Description
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Contact Information
Website
www.nextcure.comCorporate Office
- 9000 Virginia Manor Road
- Suite 200
- Beltsville, MD 20705
- United States
Corporate Office
- 9000 Virginia Manor Road
- Suite 200
- Beltsville, MD 20705
- United States
NextCure Stock Performance
As of 19-Nov-2026, NextCure’s stock price is $6.89. Its current market cap is $31M with 4.58M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.89 | $6.88 | $1.55 - $15.74 | $31M | 4.58M | 79.6K | -$6.78 |
NextCure Financials Summary
As of 30-Sep-2026, NextCure has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 6,448 | 25,046 | (48,327) | (80,277) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (40,050) | (53,644) | (52,754) | (59,023) |
| Net Income | (40,970) | (55,844) | (55,654) | (62,723) |
| Total Assets | 9,700 | 50,183 | 80,860 | 128,038 |
| Total Debt | 0 | 5,153 | 5,949 | 6,605 |
NextCure Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
NextCure Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
NextCure Comparisons
Industry
Financing
Details
NextCure Competitors (132)
One of NextCure’s 132 competitors is Nurix Therapeutics, a Formerly VC-backed company based in San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA | ||||
| Inhibrx | Formerly VC-backed | La Jolla, CA | ||||
| Apexian Pharmaceuticals | Venture Capital-Backed | Indianapolis, IN | ||||
| Kyntra Bio | Formerly VC-backed | San Francisco, CA | ||||
| Xenetic Biosciences | Corporation | Framingham, MA |
NextCure Patents
NextCure Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025245146-A2 | Anti-apoe antibodies: compositions and methods of making and using the same | Pending | 20-May-2024 | ||
| WO-2025245146-A3 | Anti-apoe antibodies: compositions and methods of making and using the same | Pending | 20-May-2024 | ||
| WO-2025155809-A2 | Compositions and methods for modulating vstm-1 mediated signal transduction | Pending | 18-Jan-2024 | ||
| WO-2025155809-A3 | Compositions and methods for modulating vstm-1 mediated signal transduction | Pending | 18-Jan-2024 | ||
| WO-2025137236-A1 | Compositions and methods for modulating cdcp1 mediated signal transduction | Inactive | 21-Dec-2023 | A61K47/6849 |
NextCure Signals
NextCure Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
NextCure Acquisitions (1)
NextCure’s most recent deal was a Reverse Merger with Avere Therapeutics for . The deal was made on 14-Jul-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Avere Therapeutics | 14-Jul-2026 | Reverse Merger | Drug Discovery |
NextCure ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.13 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
NextCure Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| NextCure (40,000 Square Foot GMP Biologics Manufacturing Facility) | Beltsville, MD |
NextCure FAQs
-
When was NextCure founded?
NextCure was founded in 2015.
-
Where is NextCure headquartered?
NextCure is headquartered in Beltsville, MD.
-
What is the size of NextCure?
NextCure has 40 total employees.
-
What industry is NextCure in?
NextCure’s primary industry is Drug Discovery.
-
Is NextCure a private or public company?
NextCure is a Public company.
-
What is NextCure’s stock symbol?
The ticker symbol for NextCure is NXTC.
-
What is the current stock price of NextCure?
As of 19-Nov-2026 the stock price of NextCure is $6.89.
-
What is the current market cap of NextCure?
The current market capitalization of NextCure is $31M.
-
Who are NextCure’s competitors?
Nurix Therapeutics, Inhibrx, Apexian Pharmaceuticals, Kyntra Bio, and Xenetic Biosciences are some of the 132 competitors of NextCure.
-
What is NextCure’s annual earnings per share (EPS)?
NextCure’s EPS for 12 months was -$6.78.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process